Claims
- 1. A process for the manufacture of a sustained release extrudate comprising the steps of:
- (a) mechanically working in a high-shear mixer, a mixture of a particulate drug and a particulate fusible carrier having a melting point from 35 to 150.degree. C., the particulate fusible carrier selected from the group consisting of a hydrophobic fusible carrier, a hydrophilic fusible carrier and mixtures thereof, at a speed and energy input which allows said particulate fusible carrier to melt or soften whereby it forms agglomerates;
- (b) extruding said agglomerates to form an extrudate.
- 2. A process according to claim 1, wherein in step (b) said agglomerates are extruded through a plurality of orifices and then formed into pieces.
- 3. A process according to claim 2, wherein step (b) further comprises the step of continuing mechanically working said pieces to form sustained release particles.
- 4. A process according to claim 1, wherein during the mechanical working step, heat is supplied thereto by microwave energy.
- 5. A process according to claim 4, wherein only part of the heat is supplied by microwave energy.
- 6. A process according to claim 1, wherein said particulate drug is selected from the group consisting of morphine, tramadol, hydromorphone, oxycodone, diamorphine and pharmaceutically acceptable salts thereof.
- 7. A process according to claim 1, wherein said hydrophobic fusible carrier is selected from the group consisting of hydrogenated vegetable oil, hydrogenated castor oil, beeswax, carnauba wax, microcrystalline wax, glycerol monostearate and mixtures thereof.
- 8. A process according to claim 3, wherein said particulate fusible carrier is added stepwise during said continuing mechanically working step.
- 9. A solid dosage form obtainable by compressing particles obtained by the process of claim 3.
- 10. A capsule for oral dosing containing particles obtained by the process of claim 3.
- 11. A solid dosage form as set forth in claim 10, wherein said drug is unstable in water.
- 12. A solid dosage form as set forth in claim 10, wherein said drug is unstable in water.
- 13. The solid dosage form of claim 9, further comprising conventional tabletting excipients.
- 14. The capsule of claim 10, further comprising conventional capsuling excipients.
- 15. The process of claim 1, wherein said hydrophobic fusible carrier is a wax.
- 16. The solid dosage form of claim 9, wherein said hydrophobic fusible carrier is a wax.
- 17. The capsule of claim 10, wherein said hydrophobic fusible carrier is a wax.
- 18. The sustained release extrudate of claim 1, wherein release control component comprising a material selected from the group consisting of a water-soluble fusible material, a particulate organic material, a particulate organic material, a particulate organic material, a particulate inorganic material and mixtures thereof is included in the mixture of step (a).
- 19. A process according to claim 3, wherein said continuing mechanically working step further includes mechanically working the pieces with a hydrophobic fusible carrier, a hydrophilic fusible carrier or mixtures thereof.
- 20. A process according to claim 3, wherein said continuing mechanically working step is repeated one or more times.
- 21. A process according to claim 3, further comprising the step of repeating steps (b) and the continuing mechanically working step one or more times.
- 22. A solid dosage form formed by compressing pieces obtained by the process claim 2.
- 23. A capsule for oral dosing containing pieces obtained by the process of claim 2.
- 24. The process of claim 2, wherein said pieces provide sustained release of said drug.
- 25. A process according to claim 19, wherein said hydrophilic fusible carrier included in the continuing mechanically working step is selected from the group consisting of a polyethylene glycol having a molecular weight of from 1,000 to 20,000 g/m and a poloxamer.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9422154 |
Nov 1994 |
GBX |
|
Parent Case Info
This application is a 371 of PCT GB95/02579.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/GB95/02579 |
11/3/1995 |
|
|
8/18/1997 |
8/18/1997 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO96/14059 |
5/17/1996 |
|
|
US Referenced Citations (144)
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 8976091 |
Jun 1992 |
AUX |